Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF.

JACC. Advances2025PMID: 40466245

View on PubMed DOI: 10.1016/j.jacadv.2025.101857

Authors

Kwaah, Patrick A; Mensah, Samuel A; Carboo, Abraham; Rashid, Hamza A; Agyemang, Emmanuel A; Appah, Grace; Frimpong, Smith K

Keywords

GLP-1 receptor agonistscardiovascular outcomesdulaglutideheart failure with preserved ejection fraction (HFpEF)non-obesesemaglutidetype 2 diabetes mellitus (T2DM)